Movetis obtains EU authorisation for the commercialisation of Resolor (prucalopride)
Prucalopride is a selective high affinity serotonin (5-HT4) receptor agonist with enterokinetic activity, indicated for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.
The approval by the European Commission means that Resolor is now approved for marketing in the 27 countries of the EU as well as Iceland, Liechtenstein and Norway. As part of its post marketing commitments Movetis has agreed to conduct further clinical studies to investigate the safety and efficacy of prucalopride in the treatment of chronic constipation in males. Furthermore it intends to initiate a clinical program to test the product in children and in opioid-induced constipation.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.